シプロイセル-T 化学特性,用途語,生産方法
説明
Sipuleucel-T is the first FDA-approved therapeutic cancer vaccine. It
is approved for the treatment of asymptomatic or minimally symptomatic
metastatic castration-resistant (hormone-refractory) prostate cancer.
Sipuleucel-T is described as a therapy rather than a precisely defined
therapeutic agent because it is an autologous vaccine that is generated
from each individual patient's own blood cells.
Originator
Dendreon (United States)
brand name
Provenge
シプロイセル-T 上流と下流の製品情報
原材料
準備製品